1. Home
  2. RAPP

as 10-07-2025 3:30pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Nasdaq

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Founded: 2022 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 439.4M IPO Year: 2024
Target Price: $37.00 AVG Volume (30 days): 1.1M
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.51 EPS Growth: N/A
52 Week Low/High: $6.43 - $42.27 Next Earning Date: 11-06-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Stock Insider Trading Activity of Rapport Therapeutics Inc. Common Stock (RAPP)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Ceesay Abraham RAPP Chief Executive Officer Sep 17 '25 Sell $26.63 76,420 $2,011,197.18 586,812
Bredt David RAPP Chief Scientific Officer Sep 15 '25 Sell $24.27 8,500 $205,648.68 421,544
Huber Reid M RAPP Director Sep 12 '25 Buy $24.48 20,400 $499,373.64 20,400
PAUL STEVEN M RAPP Director Sep 12 '25 Buy $24.74 41,666 $1,027,111.28 41,666
Young Wendy B. RAPP Director Sep 11 '25 Buy $22.60 3,500 $79,100.00 9,500
Gault Cheryl RAPP Chief Operating Officer Sep 8 '25 Sell $38.33 5,000 $191,650.00 171,928
Bredt David RAPP Chief Scientific Officer Aug 15 '25 Sell $15.38 8,500 $127,466.27 421,544

Share on Social Networks: